Method of providing patient specific immune response in amyloidoses and protein aggregation disorders

A method of treating Alzheimer's Disease pathology, which method comprises:

• selecting a subject who has Alzheimer's Disease pathology;
• and
• administering, to the selected subject an oligonucleotide or modified oligonucleotide containing at least one unmethylated B-class CpG dinucleotide motif at a dosage in a range of 0.2 mg to 20 mg per kilogram body weight of the selected subject, wherein said administering is effective to stimulate production of endogenously primed autoantibodies without co-administration of exogenous immunogens, said autoantibodies having binding specificity for one or more pathological neo-epitopes of amyloid beta or a beta-amyloid-associated protein, without stimulating production of autoantibodies having binding specificity for non-pathological epitopes of amyloid beta or a beta-amyloid-associated protein in the subject, thereby treating Alzheimer's Disease pathology.

49-50. (canceled)

An oligonucleotide or modified oligonucleotide containing at least one unmethylated B-class CpG dinucleotide motif for the treatment of a subject who has Alzheimer's Disease pathology.